Kilee Jackson, in Given, WV - Occupational Therapist

Kilee Jackson, is a Occupational Therapist based in Given, West Virginia. Kilee Jackson is licensed to practice in South Carolina (license number 4551) and her current practice location is 246 Fayes Valley Rd, Given, West Virginia. She can be reached at her office (for appointments etc.) via phone at (304) 532-3975.

NPI number for Kilee Jackson is 1144606609 and her current mailing address is 246 Fayes Valley Rd, Given, West Virginia. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1144606609.

Contact Information

	Kilee Jackson,
	246 Fayes Valley Rd, Given, WV 25245-8027
	(304) 532-3975
	Not Available

Healthcare Provider's Profile

Full Name	Kilee Jackson
Gender	Female
Speciality	Occupational Therapist
Location	246 Fayes Valley Rd, Given, West Virginia
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1144606609
Provider Enumeration Date: 08/07/2015
Last Update Date: 08/07/2015

Medical Identifiers

Medical identifiers for Kilee Jackson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1144606609	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	4551 (South Carolina)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Kilee Jackson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Kilee Jackson, 246 Fayes Valley Rd, Given, WV 25245-8027 Ph: (304) 532-3975	Kilee Jackson, 246 Fayes Valley Rd, Given, WV 25245-8027 Ph: (304) 532-3975

News Archive

Perceived side effects to Tamoxifen making many quit breast cancer drug

According to a new study by a team of researchers led by the Queen Mary University of London, women who have been prescribed Tamoxifen as a cancer preventive are failing to take the medicine owing to perceived side effects from the drug. Some of the symptoms that they report as distressing are caused naturally by the disease condition rather than the drug explain researchers.

ODAC recommends ApoPharma's Ferriprox for FDA approval to treat transfusional iron overload

ApoPharma Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 10 - 2 to recommend that the FDA grant accelerated approval of Ferriprox (deferiprone), an oral iron chelator, for the treatment of patients with transfusional iron overload when current chelation therapy is inadequate.

Researchers examine advantages of being married to physician

Physicians tend to marry later and their marriages last longer even as they face the challenges, like others with demanding professions, of giving time and attention to their partners and families.

Study finds disparities in discontinuing diabetes drug rosiglitazone following FDA safety alert

Among older adults with diabetes, certain subgroups-including white patients and those with lower incomes-were slower to discontinue the diabetes drug rosiglitazone after a US Food and Drug Administration safety alert, reports a study in the April issue of Medical Care.

Trevena completes $35M Series B financing

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor biased ligands, announced today that it has completed a $35 million Series B financing. Existing investors Polaris Venture Partners and New Enterprise Associates led the round, with all other existing Trevena investors - Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company - also participating in the financing.

Kilee Jackson, - Occupational Therapist in Given, WV